首页> 美国卫生研究院文献>Autophagy >Restoration of mitophagy ameliorates cardiomyopathy in Barth syndrome
【2h】

Restoration of mitophagy ameliorates cardiomyopathy in Barth syndrome

机译:线粒体自噬的恢复可改善 Barth 综合征患者的心肌病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Barth syndrome (BTHS) is an X-linked genetic disorder caused by mutations in the TAFAZZIN/Taz gene which encodes a transacylase required for cardiolipin remodeling. Cardiolipin is a mitochondrial signature phospholipid that plays a pivotal role in maintaining mitochondrial membrane structure, respiration, mtDNA biogenesis, and mitophagy. Mutations in the TAFAZZIN gene deplete mature cardiolipin, leading to mitochondrial dysfunction, dilated cardiomyopathy, and premature death in BTHS patients. Currently, there is no effective treatment for this debilitating condition. In this study, we showed that TAFAZZIN deficiency caused hyperactivation of MTORC1 signaling and defective mitophagy, leading to accumulation of autophagic vacuoles and dysfunctional mitochondria in the heart of Tafazzin knockdown mice, a rodent model of BTHS. Consequently, treatment of TAFAZZIN knockdown mice with rapamycin, a potent inhibitor of MTORC1, not only restored mitophagy, but also mitigated mitochondrial dysfunction and dilated cardiomyopathy. Taken together, these findings identify MTORC1 as a novel therapeutic target for BTHS, suggesting that pharmacological restoration of mitophagy may provide a novel treatment for BTHS.Abbreviations: BTHS: Barth syndrome; CCCP: carbonyl cyanide 3-chlorophenylhydrazone; CL: cardiolipin; EIF4EBP1/4E-BP1: eukaryotic translation initiation factor 4E binding protein 1; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; KD: knockdown; KO: knockout; LAMP1: lysosomal-associated membrane protein 1; LV: left ventricle; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MEFs: mouse embryonic fibroblasts; MTORC1: mechanistic target of rapamycin kinase complex 1; OCR: oxygen consumption rate; PE: phosphatidylethanolamine; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PINK1: PTEN induced putative kinase 1; PRKN/Parkin: parkin RBR E3 ubiquitin protein ligase; qRT-PCR: quantitative real-time polymerase chain reaction; RPS6KB/S6K: ribosomal protein S6 kinase beta; SQSTM1/p62: sequestosome 1; TLCL: tetralinoleoyl cardiolipin; WT: wild-type.
机译:巴斯综合征 (BTHS) 是一种由 TAFAZZIN/Taz 基因突变引起的 X 连锁遗传病,该基因编码心磷脂重塑所需的转酰化酶。心磷脂是一种线粒体特征磷脂,在维持线粒体膜结构、呼吸、mtDNA 生物发生和线粒体自噬中起关键作用。TAFAZZIN 基因突变会消耗成熟的心磷脂,导致 BTHS 患者的线粒体功能障碍、扩张型心肌病和过早死亡。目前,没有有效的治疗方法来治疗这种使人衰弱的疾病。在这项研究中,我们发现 TAFAZZIN 缺乏导致 MTORC1 信号传导过度激活和线粒体自噬缺陷,导致自噬液泡和线粒体功能障碍在 Tafazzin 敲除小鼠(BTHS 的一种啮齿动物模型)的心脏中积累。因此,用雷帕霉素(一种有效的 MTORC1 抑制剂)治疗 TAFAZZIN 敲低小鼠,不仅可以恢复线粒体自噬,还可以减轻线粒体功能障碍和扩张型心肌病。综上所述,这些发现将 MTORC1 确定为 BTHS 的新型治疗靶点,表明线粒体自噬的药理学恢复可能为 BTHS 提供一种新的治疗方法。缩写: BTHS: 巴特综合征;CCCP: 羰基氰化物 3-氯苯腙;CL: 心磷脂;EIF4EBP1/4E-BP1: 真核翻译起始因子 4E 结合蛋白 1;GAPDH: 甘油醛-3-磷酸脱氢酶;KD: 敲低;KO:敲除;LAMP1: 溶酶体相关膜蛋白 1;LV: 左心室;MAP1LC3/LC3: 微管相关蛋白 1 轻链 3;MEFs: 小鼠胚胎成纤维细胞;MTORC1: 雷帕霉素激酶复合物 1 的机制靶标;OCR:耗氧率;PE: 磷脂酰乙醇胺;PIK3C3/VPS34: 磷脂酰肌醇 3-激酶催化亚基 3 型;PINK1: PTEN 诱导的推定激酶 1;PRKN/Parkin:parkin RBR E3 泛素蛋白连接酶;qRT-PCR: 定量实时聚合酶链反应;RPS6KB/S6K: 核糖体蛋白 S6 激酶 β;SQSTM1/p62: 螯合体 1;TLCL: 四亚油酰心磷脂;WT: 野生型。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号